Infantile Spasms Therapeutics Market to Grow with a CAGR of 5.95% through 2028
Improvements in diagnostic techniques and innovative
therapeutic approaches are expected to drive the Global Infantile Spasms
Therapeutics Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “Infantile
Spasms Therapeutics Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Infantile
Spasms Therapeutics Market stood at USD 355.12 million in 2022 and is
anticipated to grow with a CAGR of 5.95% in the forecast period, 2024-2028.
This can be attributed to growing investment in research. Pharmaceutical
companies and research institutions are dedicating significant resources to
studying the underlying causes and potential treatments for infantile spasms.
Clinical trials and research studies are underway to investigate the efficacy
and safety of various therapeutic interventions. This commitment to research is
driving the market's growth by expanding the knowledge base and treatment
possibilities.
Furthermore, innovations in drug delivery systems are
improving the administration of therapies. This includes extended-release
formulations, implantable devices, and non-invasive methods. These advancements
enhance treatment adherence and overall patient experience.
Infantile spasms therapeutics encompass the treatment
methods employed to address seizures or epilepsy syndrome in young children,
typically ranging from four months to one year of age. An episode of these
spasms is characterized by sudden stiffening of the body, forward bending of
the arms, legs, and head, arching of the back, and brief, subtle seizures. The
underlying causes of infantile spasms may include brain tumors, birth injuries,
brain infections, and genetic alterations. There exist several therapeutic
choices for managing infantile spasms, including the administration of
steroids, hormone therapy involving corticotropin injection gel and
glucocorticoids, as well as the use of antiseizure medications. Achieving
sustained results with infantile spasms therapeutics is more likely when they
are initiated within three weeks following the onset of spasms. Treatment can
involve either a single therapy approach (monotherapy) or a combination of
therapies. The diagnosis of infantile spasms is typically established through a
physical examination, a neurological assessment, brain MRI scans, and blood and
urine tests.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Infantile SpasmsTherapeutics Market.”
The Global Infantile Spasms Therapeutics Market is
segmented into dosage, route of administration, regional distribution, and
company.
Based on its dosage, Liquid dosage forms are poised to
dominate the Global Infantile Spasms Therapeutics Market and maintain their
stronghold in the forecast years for several compelling reasons. Firstly,
liquid medications offer precise dosing, particularly crucial in pediatric care
where accurate administration is paramount. This accuracy minimizes the risk of
under or overdosing, ensuring the safety and efficacy of treatment. Secondly,
liquid formulations are often preferred by parents and caregivers due to their
ease of administration, especially for infants and young children who may
struggle with swallowing pills or capsules. Additionally, liquid medications
can be conveniently mixed with food or drink, making them more palatable and
increasing patient compliance. Moreover, the flexibility of liquid dosages
allows for adjustments in line with a child's changing weight and needs,
further enhancing their suitability for this dynamic patient population. As a
result, liquid dosage forms are poised to remain at the forefront of infantile
spasms therapeutics, catering to both medical and practical considerations, and
continue their dominance in the foreseeable future.
Based on route of administration, the parenteral route
of administration is set to dominate the Global Infantile Spasms Therapeutics
Market and sustain its dominance in the forecast years for several compelling
reasons. First and foremost, parenteral delivery methods, such as intravenous
and intramuscular injections, ensure rapid and precise drug delivery, crucial
in managing acute conditions like infantile spasms. This swift onset of action
can be a decisive factor in preventing the progression of the disease and
minimizing complications. Moreover, the parenteral route eliminates concerns
related to gastrointestinal absorption variability, which can be unpredictable
in infants and young children. Additionally, healthcare professionals can
closely monitor and titrate the dosage when administering medications through
the parenteral route, ensuring tailored and effective treatment. As the demand
for highly controlled and efficient therapies for infantile spasms continues to
grow, the parenteral route is expected to maintain its dominance due to its
proven effectiveness, reliability, and life-saving capabilities.
Major companies operating in Global Infantile
Spasms Therapeutics Market are:
- Merck KGaA
- Novartis AG
- Sanofi SA
- Pfizer Inc
- Johnson & Johnson
- Abbott Laboratories Inc
- Teva Pharmaceutical Industries Ltd
- Bausch Health Companies Inc.
- AstraZeneca PLC
- GSK PLC
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The future of the global infantile spasms
therapeutics market is marked by optimism and innovation. The upcoming trends
in personalized medicine, gene therapies, and neuroinflammation targeting
represent exciting possibilities for patients and their families.
Collaboration, technological advancements, and a patient-centered approach are
expected to drive progress in the field, offering hope for improved outcomes
and quality of life for infants affected by this rare and severe form of
epilepsy. As researchers, healthcare providers, and pharmaceutical companies
continue to push the boundaries of knowledge and innovation, the future holds
great promise for the treatment of infantile spasms,” said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based management consulting
firm.
“Infantile Spasms Therapeutics Market By
Dosage (Liquid, Solid), By Route of Administration
(Oral, Parenteral), By
Region, By Competition Forecast
& Opportunities, 2018-2028F”, has evaluated the future growth potential of Global
Infantile Spasms Therapeutics Market and provides statistics & information
on market size, structure and future market growth. The report intends to
provide cutting-edge market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the
emerging trends along with essential drivers, challenges, and opportunities in
Global Infantile Spasms Therapeutics Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com